Eplontersen: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), NICE (England) and SMC (Scotland), among others, recommended or restricted eplontersen, while AOTMIT (Poland) did not recommend it.
Every record falls within a 1.5-year window, 27 Nov 2024 to 18 May 2026 — a compressed review cycle.
No assessment is on file from HAS (France), PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 7 of 8 records date from 2023 or later.
Against its own class, eplontersen is an outlier: 83% of its decisive outcomes were positive, where molecules sharing ATC class N07X average 56%.
NICE (England) was first to assess eplontersen, on 27 Nov 2024; AOTMIT (Poland) did not open a file until 18 May 2026 — a moderate spread of 1.5 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 7 dated records fall in 2025 alone.
Restriction is doing real work here: 2 of 6 decisive outcomes narrowed eplontersen to a subgroup rather than accepting or refusing it outright, at NICE (England) and TLV (Sweden).
8 of the 18 agencies in this archive hold a record for eplontersen.
The full ledger for eplontersen reads 3 recommended, 2 restricted, 1 not recommended and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 16 Oct 2025 | Wainzua — benefit assessment §35a | added benefit: not proven | source |
| TLV (Sweden) | 30 Sep 2025 | Wainzua ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| ZIN (Netherlands) | 20 Aug 2025 | Advies - vergoed eplontersen (Wainzua®) voor de behandeling van een bepaalde vorm van amyloïdose | reimbursed | source |
| CIPM (Spain) | 19 Jun 2025 | Indicación terapéutica autorizada: Tratamiento de la amiloidosis hereditaria por transtiretina (ATTRh) en pacientes adul… | financed by the SNS · art. 92 a, c, e | source |
| SMC (Scotland) | 7 Apr 2025 | For treatment of adult patients with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTRv). | accepted | source |
3 further decisions for eplontersen, across 3 agencies, are not shown here. They include the most recent record on file, 18 May 2026 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 3 further source documents.
Related molecules
- tafamidis — same ATC class N07X — Other nervous system
- vutrisiran — same ATC class N07X — Other nervous system
- pitolisant — same ATC class N07X — Other nervous system
- fampridine — same ATC class N07X — Other nervous system
- omaveloxolone — same ATC class N07X — Other nervous system
- patisiran — same ATC class N07X — Other nervous system
Coverage: 8 decisions for eplontersen from 8 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class N07X — Other nervous system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.